Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

AMP Releases CYP3A4 and CYP3A5 Genotyping Assay Recommendations

The Association for Molecular Pathology (AMP), the world’s leading professional society for molecular diagnostics, released consensus recommendations today to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, encourage standardization of testing across labs, and better patient care.

11 Jul 2023

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021

New genetic classifier can predict the sensitivity of chemotherapy for breast cancer

A team of researchers recently postulated a genetic classifier with the ability to predict the sensitivity of neoadjuvant chemotherapy for breast cancer in the area of tumor molecular markers.

16 Sep 2021

Constitutive BAK/MCL1 complexes could predict sensitivity of chemotherapy drugs, research shows

A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.

16 Sep 2021